... cancer or cardiovascular disease.
“The bottom-line message is that a portion of those who survive Hodgkin’s Lymphoma continue to have significant health needs beyond their five-year ‘cure’ mark,” ...
... as follicular lymphoma. While there have been studies to investigate the usefulness of PET in patients with lymphoma and research into the effectiveness of radioimmunotherapy, no data were available ...
... . "The mouse we created gives us a very good, predictive model of B-cell lymphomas, which can be used to explore not only these and related cancers, but also autoimmune disease and basic immunology."
... for treating mantle cell lymphoma.
"A better understanding of the epidemiology of mantle cell lymphoma, the development of novel agents, more research funding and increased public awareness are all ...
... IL-21 production could lead to the development of new therapy strategies for Hodgkin lymphoma in the future, according to the researchers in Professor Bernd Dörken's laboratory, who collaborated with ...
Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient's risk of dying. That is the finding of a new study published in the December 1, 2008 ...
Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma patient's risk of dying.
... and by clogging up the mechanism for eliminating poorly made ones.
Mantle cell lymphoma, an aggressive cancer of the lymphatic system that mostly occurs in middle age, responds initially to ...
... (MLP) is an unusual form mantle cell lymphoma characterized by polyps throughout the gastrointestinal tract. ... man with adult T-cell leukemia/lymphoma (ATLL). This will be published on November 14, 2008 ...
... of patients is needed. This positive effect was seen regardless of the treatment approach for the lymphoma. Treatments included observation only, rituximab alone or rituximab in combination with ...
... reported.
Prolonged myelosuppression also makes treatment much more difficult if a patient's lymphoma recurs, Samaniego said. "Patients treated with myelosuppressing agents have a difficult time ...
... , drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a Mayo Clinic study presented today at the 50th Annual Meeting of the ...
... -Presbyterian/Columbia, now focusing on determining how the drug works in T-cell lymphoma, and on how best to combine it with other drugs to improve the treatment of patient with hematologic cancers.
... studied patient tumor chromosomal translocations to gain an important clue as to how the most common lymphomas are caused. The study demonstrated that these breaks are focused at CpG sites, short ...
... trial of pralatrexate, a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma.
